Is Vertex Pharmaceuticals Stock a Buy?

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date.Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales. The company is also poised to benefit from two recent new drug approvals by the FDA, alongside several upcoming milestones in its extensive clinical pipeline portfolio.Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool